Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Clinical use of Colony Stimulating Factors

The Clinical use of Colony Stimulating Factors Colony stimulating factors and interleukins regulate proliferation, differ­ entiation, and functional activation of hematopoietic cells of multiple lineages. These hematopoietic growth factors are proving effective in vivo in stimulation of granulopoiesis in clinical situations associated with myelosuppression. G-CSF and GM-CSF promote accelerated granulocyte recovery following chemotherapy, or allogeneic or autologous bone mar­ row transplantation, in patients with cancer. In congenital defects of granulocyte production or in acquired disorders such as idiopathic neutro­ penia or aplastic anemia, CSF administration can lead to recovery of functioning granulocytes. This has resulted in a reduction in the morbidity and mortality associated with these diseases and now permits both a dose and a schedule intensification of chemotherapy. In myeloid leukemia and mye10dysplastic syndromes, CSF treatment, particularly G-CSF, has proved effective for certain patients in improving neutrophil, platelet, and occasionally red cell production while reducing blast cells. The recombinant growth factors are generally well tolerated with few limiting toxicities at dose levels that effectively stimulate hematopoiesis. INTRODUCTION Colony stimulating factors (CSF) belong to an ever expanding family of hematopoietic growth factors that includes ten interleukins (IL-I-IO) and 1 59 0732-0582/91/0410-0159 $02.00 MOORE erythropoietin. Initially defined and identified by their ability to stimulate colony formation http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Immunology Annual Reviews

The Clinical use of Colony Stimulating Factors

Annual Review of Immunology , Volume 9 (1) – Apr 1, 1991

Loading next page...
 
/lp/annual-reviews/the-clinical-use-of-colony-stimulating-factors-mAbdHBakTv

References (46)

Publisher
Annual Reviews
Copyright
Copyright 1991 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0732-0582
eISSN
1545-3278
DOI
10.1146/annurev.iy.09.040191.001111
pmid
1910675
Publisher site
See Article on Publisher Site

Abstract

Colony stimulating factors and interleukins regulate proliferation, differ­ entiation, and functional activation of hematopoietic cells of multiple lineages. These hematopoietic growth factors are proving effective in vivo in stimulation of granulopoiesis in clinical situations associated with myelosuppression. G-CSF and GM-CSF promote accelerated granulocyte recovery following chemotherapy, or allogeneic or autologous bone mar­ row transplantation, in patients with cancer. In congenital defects of granulocyte production or in acquired disorders such as idiopathic neutro­ penia or aplastic anemia, CSF administration can lead to recovery of functioning granulocytes. This has resulted in a reduction in the morbidity and mortality associated with these diseases and now permits both a dose and a schedule intensification of chemotherapy. In myeloid leukemia and mye10dysplastic syndromes, CSF treatment, particularly G-CSF, has proved effective for certain patients in improving neutrophil, platelet, and occasionally red cell production while reducing blast cells. The recombinant growth factors are generally well tolerated with few limiting toxicities at dose levels that effectively stimulate hematopoiesis. INTRODUCTION Colony stimulating factors (CSF) belong to an ever expanding family of hematopoietic growth factors that includes ten interleukins (IL-I-IO) and 1 59 0732-0582/91/0410-0159 $02.00 MOORE erythropoietin. Initially defined and identified by their ability to stimulate colony formation

Journal

Annual Review of ImmunologyAnnual Reviews

Published: Apr 1, 1991

There are no references for this article.